Nymox Pharmaceutical Corporation
NYMXF
$0.1364
$0.026424.00%
OTC PK
| 09/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 4.35M | 2.10M | 2.10M | 2.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 8.35M | 1.81M | 1.81M | 2.28M |
| Operating Income | -- | -8.35M | -1.81M | -1.81M | -2.28M |
| Income Before Tax | -- | -8.84M | -4.87M | -4.87M | -5.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -8.84 | -4.87 | -4.87 | -5.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -8.84M | -4.87M | -4.87M | -5.33M |
| EBIT | -- | -8.35M | -1.81M | -1.81M | -2.28M |
| EBITDA | -- | -8.34M | -1.80M | -1.80M | -2.21M |
| EPS Basic | -- | -0.10 | -0.05 | -0.05 | -0.06 |
| Normalized Basic EPS | -- | -0.06 | -0.03 | -0.03 | -0.04 |
| EPS Diluted | -- | -0.10 | -0.06 | -0.06 | -0.07 |
| Normalized Diluted EPS | -- | -0.06 | -0.03 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | -- | 365.73M | 363.70M | 363.70M | 362.81M |
| Average Diluted Shares Outstanding | -- | 365.73M | 363.70M | 363.70M | 362.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |